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ABSTRACT 
Impact of Renal Lymphatic Hyperplasia on Blood Pressure Regulation 
  
Gabriella Abouelkheir 
Department of Chemistry 
Texas A&M University 
 
Research Advisor: Dr. Joseph Rutkowski 
Department of Medical Physiology 
Texas A&M University College of Medicine 
 
 
 Chronic high blood pressure, or hypertension, is identified as a risk factor for heart 
disease, stroke, and chronic kidney disease. The primary cause of most hypertension is increased 
peripheral vascular resistance that is controlled, in large part, by the kidney’s water handling. In 
the kidney, specific immune cell subsets and overall renal inflammation have both been 
identified as drivers of hypertension in preclinical models. Lymphatic vessels serve as a route of 
both fluid and immune cell clearance and their expansion, lymphangiogenesis, is necessary for 
the resolution of tissue inflammation. We hypothesized that by increasing renal 
lymphangiogenesis, renal inflammation would be reduced and blood pressure would be 
normalized during salt-sensitive hypertension. To investigate the role of renal immune cell 
trafficking in instances of blood pressure challenge, we employed a murine model of inducible 
renal lymphatic expansion. Mice expressing a lymphatic growth factor, vascular endothelial 
growth factor (VEGF)-D, under the control of a TRE-promoter were crossed with mice 
expressing a Kidney Specific Protein-regulated transactivator (rtTA). Upon administration of 
doxycycline, the rtTA-dox complex binds to the TRE promoter region, causing transcription of 
VEGF-D only in renal tubular epithelial cells. The resultant kidney-specific VEGF-D 
2 
 
overexpression caused expansion of the existing renal lymphatic network in addition to 
generating de novo lymphangiogenesis in the cortex of “Kid-VD” mice. We then utilized the 
Kid-VD mouse model during an established rodent hypertension regimen of nitric oxide 
inhibition and high salt diet loading to identify the impact – through weekly blood pressure 
measures - and mechanism – by cellular, protein, and RNA analysis – of expanded renal 
lymphatics on blood pressure regulation. Lymphatic circulation may thus provide a new target 
for the treatment of chronic hypertension and its associated co-morbidities. 
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VEGFR-3 vascular endothelial growth factor receptor 3 
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rtTA  reverse tetracycline transactivator 
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VEGF  vascular endothelial growth factor 
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CHAPTER I 
INTRODUCTION 
 
Lymphatics History  
Compared to many other areas of study, lymphatics are understudied, underfunded, and 
undervalued. Despite documentation of what is understood to be the lymphatics in the 4
th
 century 
B.C., it was not until the mid-16
th
 and 17
th
 centuries A.D. that significant strides in the field were 
made
1
. During this time period an increase in the accepted practice of human cadaver dissections 
allowed for significant anatomical descriptions of this system, though physiological conclusions 
were merely associations with ascites, edema, and cancer metastasis.
1,2
 More surgical approaches 
to studying lymphatics nearly 100 years later led to the conclusion that the system is primarily 
responsible for absorption,
1
 specifically of fluid extravastated from their cardiovascular 
counterparts. This process of fluid leakage was eventually determined by Ernest Starling who 
described the relationship between hydrostatic and oncotic pressure that drives the fluid to leave 
the blood vasculature in the first place.
3
 Now, there is a general understanding that the lymphatic 
system is responsible for more beyond returning lost fluid from the interstitium and plays key 
roles in antigen recognition and response, macromolecular transport, and several pathological 
states beyond cancer metastasis. Despite these important functions, research in the field of 
lymphatics has been hindered by limited lymphatic endothelium-specific markers. Relatively 
recently, markers such as vascular endothelial growth factor receptor-3 (VEGFR-3), podoplanin, 
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), and pospero homeobox 1 (prox1) 
were identified to be reliable lymphatic endotheial cell (LEC) identifiers.
4
 Despite these 
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challenges to discovery, however, the increasingly prominent function of this system in 
numerous diseases necessitates increased investigation and is the fundamental basis of this study.  
 
Basic Functions of the Lymphatic System  
The lymphatic system plays several key roles in the body that are necessary for 
maintaining homeostasis. The first of these functions is that of fluid regulation. The lymphatics 
are fundamentally responsible for returning fluid leaked by the blood vessels into system 
circulation. This begins with the loss of fluid from the blood vasculature due to differences in 
hydrostatic and oncotic pressures between the blood and interstitium.
1
 As this interstitial fluid is 
taken up by the lymphatic vessels, it is transported along with certain cells and macromolecules 
through the lymphatic network (and several lymph nodes) until it passes into the thoracic duct is 
returned to system circulation through the inferior vena cava.
5
 A majority of the cells taken up in 
the lymph are macrophages and dendritic cells which present antigens to the draining lymph 
node, stimulating an immune response when necessary.
6-8
 Additionally, the lymphatic vessels are 
responsible for taking up fatty acids in the gut and transporting for processing and later use.
9
 
These represent the homeostatic roles of the lymphatic system.  
 
Lymphatics and Inflammation 
The importance of the lymphatics extends far beyond homeostatic regulation, however, 
and enters pathological conditions where the lymphatic system can be praised for assisting in the 
resolution of the disease state, or blamed for worsening it. Whether the result is beneficent or 
harmful depends on the balance between different functions of the system. Primarily, as 
previously stated, the major function of the network is that of fluid collection, therefore it is 
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reasonable to conclude that in instances of edema, ascites, and general conditions of fluid 
retention, the lymphatics present an escape for fluid buildup.
1
 Simultaneously, however, lymph 
nodes are responsible for producing responses to the immune cells received from the periphery, 
complicating the seemingly beneficial lymphatic vessels.
10
 Consider the case of inflammation (of 
primary interest in this study). Within the cocktail of cells and chemicals taken up by the 
lymphatics are both pro- and anti-inflammatory cytokines including interleukin1 (IL-1), IL-10, 
respectively.
11
 This requires the resulting bodily response to be a balance between the seemingly 
contradicting cells presented to the lymph nodes. Moreover, whether the response supports or 
hinders inflammation is further compounded by the amount of cytokine, its target cell, and the 
timing.
11
 Furthermore, the issue of the role of the lymphatic system in inflammation is 
compounded by the presence of a process appropriately termed inflammation-associated 
lymphangiogenesis (IAL). IAL is the process by which the existing lymphatic vasculature is 
expanded or a new vasculature is created de novo in response to pro-lymphangiogenic factors 
secreted by immune cell subsets present in conditions of inflammation.
12
 Along with these 
factors such as vascular endothelial growth factor C (VEGF-C) and VEGF-D, are factors that are 
anti-lymphangiogenic, such as interferon gamma (IFNγ) produced by T-cell subsets.13,14 The 
balance between these two groups is believed to determine the extent of IAL observed, the 
degree of benefit/harm, and the newly-formed network’s eventual regression (if any).12,13,15,16 
Setting and cause also play a significant role in IAL and its resulting effects. For example, IAL is 
known to both occur and be harmful to keteroplasties,
17-20
 cardiac transplants
21
 and other 
allografts, beneficial under conditions of both chronic and acute skin inflammation
22,23
and 
myocardial infarctions,
24,25
 and ambiguous in the realm of airway inflammation
26
 and renal 
inflammatory pathologies.
27
 This necessitates the question of whether IAL can be targeted as a 
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therapeutic in certain pathological instances, which is what several groups are currently 
investigating. A summary of the effects of IAL in various tissues can be found in this review
28
 
(Appendix), and is graphically represented in Figure 1.  
 
 
Figure 1. A schematic depicting the potential effects of IAL. Instances of inflammation can 
induce lymphangiogenesis with particular chemokines. The new lymphatics then serve as an exit 
route for fluid, immune cells, and cytokines resulting in resolution of the inflammation. In 
instances of inflammation when the lymphatic vasculature does not expand, however, this can 
lead to unresolved inflammation. In times when the lymphatics expand and the resulting network 
is dysfunctional, this can worsen the pathology and result in persistent inflammation. Figure 
reprinted with permission from Abouelkheir et al. 2017. 884-895.
28
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Inflammation and Hypertension 
One particular pathological state becoming increasingly frequent as a secondary 
complication of diseases such as diabetes and affecting a large portion of the population and 
having a negative compounding effect on health is hypertension.
29
 Hypertension is a disease 
characterized by persistently increased blood pressure in which inflammation and immune cells 
have implicated as key players.
30
 Examples of these influential participants include Th17 cells 
which are pro-inflammatory and pro-hypertensive, in contrast to regulator T-cells (Tregs) which 
play the opposing roles, implicating an immune basis to the intimate relationship between 
inflammation and hypertension.
31
 Recently, De Miguel et al. investigated the infiltration of 
immune cells (particularly T lymphocyte subsets) into the kidney in cases of hypertension 
(specifically Dahl salt-sensitive hypertension).
32
 Considering the role of the lymphatic system in 
immune cell trafficking and inflammation, in addition to the role of immune cells and 
inflammation in the development of hypertension, this begs the question of whether IAL is at 
play in cases of hypertension. To investigate this, our group sought to generate an expanded 
renal lymphatic network in murine subjects
33
 submitted to various blood pressure challenges to 
determine any observable effect. 
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CHAPTER II 
METHODS 
 
Experimental Design 
Pathway of Importance 
 To choose a useful mouse model, it is important to note the signaling pathway of interest. 
In this case, the desired result is an expansion of the lymphatic network, a process achieved 
through VEGFR-3 signaling.
33
 The primary ligands for VEGFR-3 are VEGF-C and VEGF-D-
secreted growth factors.
34
 It is important to note that while both of these ligands also participate 
in VEGFR-2 signaling on blood endothelium in humans, murine VEGF-D specifically binds 
only VEGFR-3 in the mouse.
34
 Therefore, to exclusively stimulate lymphangiogenesis in the 
murine models, it is important to do so through VEGF-D signaling only, which was the model 
used in this study, generated and maintained by the Rutkowski group at the Texas A&M Health 
Science Center.  
 
The Mouse Model 
To perform the mouse model, mice having VEGF-D under the control of a tetracycline 
response element (TRE) promoter were crossed with mice having a tissue specific reverse 
tetracycline transactivator (rtTA) by the Rutkowski group.
33
 The resulting offspring, once 
induced with doxycycline, will then have overexpression of the protein VEGF-D, stimulating 
lymphangiogenesis in the tissue of interest (Figure 2). In this study, the rtTA is under the control 
of Cdh16, or the kidney specific protein (KSP), causing the rtTA to be expressed throughout the 
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renal tubular epithelium.
35
 The kidney was chosen due to recent evidences of pro-inflammatory 
immune cell infiltration of the kidney in response to hypertension.
32
  
 
 
Figure 2. Scheme depicting genetic construction of VEGF-D overexpressing mouse. In this 
study, doxycycline was added to the drinking water given to the mice. (Adapted with permission 
from Lammoglia et al. 2016. H384-H394.
33
) 
 
The Experimental Conditions 
Mice carrying the TRE-VEGF-D transgene were crossed to mice having a kidney-
specific protein rtTA (KSP-rtTA). Mice from the resulting litter were genotyped (confirmed by 
qPCR analysis) for the presence of the rtTA and VEGF-D transgenes. Mice containing both 
transgenes, “Kid-VD” mice, were the test subjects with “WT” controls lacking one of the 
transgenes (and, hence, no inducibility). All experiments were performed with adult male mice 
only. For the extent of the study, all ten male mice from the three litters received water 
containing 200 mg/mL doxycyline. This water was remade twice weekly. After one week, five of 
the mice received water containing both 200 mg/mL doxycycline and 0.5 mg/mL L-Nitro-
Arginine Methyl Ester (L-NAME), a nitric oxide (NO) inhibitor that increases blood pressure. 
The other five mice continued receiving water containing only doxycycline. This procedure 
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resulting in four total conditions: Kid-VD mice receiving dox water only (n=3), WT mice 
receiving dox water only (n=3), Kid-VD mice receiving dox and L-NAME water (n=3) and WT 
mice receiving dox and L-NAME water (n=2). At the end of four weeks, the mice were 
sacrificed and their kidneys were collected for further analysis. All animal study protocols were 
previously approved by the Institutional Animal Care and Use Committee at Texas A&M 
University.  
Another cohort of KSP-rtTA mice was bred for a second blood pressure measurement 
experiment. This cohort consisted of 8 Kid-VD positive male mice, 5 control male mice, 3 Kid-
VD positive female mice, and 3 control female mice (one Kid-VD female mouse was lost on 
week 6 of the experiment). All these mice received 0.5 mg/mL L-NAME water for 2 weeks, 
followed by one week of tap water, and 200 mg/L dox water for 4 weeks. These mice received 
normal chow for the first 4 weeks, and high-salt chow (4% NaCl) after one week of dox for the 
final 3 weeks. See Table 1 for a summary of this protocol. After this time point all of the mice 
were sacrificed, and their kidneys and renal lymph nodes were collected for further analysis. This 
protocol is expected to result in hypertension for blood pressure measurements of weeks 1-2, a 
slight elevation in blood pressure from baseline weeks 3-4, and hypertension (higher than weeks 
1-2) for weeks 5-7. All animal study protocols were previously approved by the Institutional 
Animal Care and Use Committee at Texas A&M University.  
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Table 1. Table depicting water and feed conditions for second blood pressure experiment.  
 Water Feed 
Week 0 L-Name Normal 
Week 1 L-Name Normal 
Week 2 Tap Normal 
Week 3 Dox 200 Normal 
Week 4 Dox 200 High Salt 
Week 5 Dox 200 High Salt 
Week 6 Dox 200 High Salt 
Week 7 Sac Sac 
 
 
Immunofluorescence 
Immediately following tissue harvesting, one kidney was fixed in formalin and sent to the 
Texas A&M VIBS Histology Laboratory where the samples were embedded in paraffin and 
sectioned sagitally in 3 µm-thick sections. Sections were deparaffinized using xylenes and 
rehydrated using a series of ethanol solutions. Subsequently, tissues were labeled with primary 
antibodies to murine lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) (goat 
polyclonal; R&D Systems) and podoplanin (goat polyclonal; R&D Systems) on separate 
sections. Secondary labeling was achieved with Alexafluor 488-labeled donkey antibodies (Life 
Technologies, Carlsbad, CA). Immunofluorescence images were then obtained using a Nikon 
Eclipse E600 microscope. Images were captured using NIS-Elements imaging software.  
 
RNA Preparation and Quantitative Real-Time RT-PCR 
Immediately after harvesting, one quarter of each kidney (containing both cortex and 
medulla) was flash frozen in liquid N2 for RNA analysis. For RNA extraction, samples were 
ground into a fine powder using a mortar and pestle and the extraction was performed using a 
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Qiagen RNeasy Mini Kit, following the contained manufacturer’s instructions (Qiagen, 
Germantown, MD). cDNA was obtained from 1 ug of the extracted RNA using the iScript cDNA 
Synthesis kit instructions (Bio-Rad Laboratories, Hercules, CA). The resulting cDNA was mixed 
with Power SYBER Green PCR Master Mix (Applied Biosystems) with the corresponding gene 
primers on an Applied Biosystems 7900 quantitative PCR machine for quantitative real time RT-
PCR relative expression analysis (see Table 2 for primer sequences).  Values were normalized to 
ubiquitin expression and subsequently to the corresponding expression of the WT mice of the 
same experimental condition. Statistical significance was determined using a Student’s T-test 
with a level of significance set to 0.05.  
 
Table 2a. Table containing forward sequences for primers used in qPCR analysis. Primers 
not listed were obtained from a collaborating lab.  
Gene Forward 
CD11c GATGCGGTGGAACACTTTCT 
CD3e ACCAAGAAGAGCGACTTCCA   
CD4 CTTTGGCTATGGGCTTCCAGTC 
CD8a CGGCGGCCTGTTTGCAGT 
F480 ACAAAGAAGTGGCCGAGAGA   
FGFR1 GAGAAAGTCAACCTCCTCTCTG 
FoxP3 GCTCTTACTGACTGGCATGAG 
GATA3 CCGTTGACCCGCTTTCTGT 
IL10 CTGGATAGCCTTTCTTCTGCTG 
IL6 TCCTAGCTGTCACTCAAGGGA 
LYVE1 CTACCGGGTTCGGATGTAAGTC 
mKlotho GGTCCACAGACATCATGGAA 
TNFa GCCCTGCTGTGGTCTCACTAC 
Ubiq ATCAGAAGATCGGGCGCTGTTGTA 
VEGFA GGAGATCCTTCGAGGAGCACTT 
VEGFC CTGACAAGCAGTTTCAGGCTTGGT 
VEGFD AAATCGCGCACTCTGAGGA   
VEGFR2 GAGGATACCACTCCCAACAGACC 
VEGFR3 GCCCAGTGTTACCACCAAGAAG  
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Table 2b. Table containing reverse sequences for primers used in qPCR analysis. Primers 
not listed were obtained from a collaborating lab.  
Gene Reverse 
CD11c ACTGTCCTCGACTTCCGAGA 
CD3e AACCAGGAGAACCCCAGAGT   
CD4 GCAAGGAGGACAGAGTTTATCGTG 
CD8a TTGTGGCGGATGGCATTCTTC 
F480 CGGTGAAATAGGGCAAAAGA   
FGFR1 GAAGACTCCTCCCAGGTATATG 
FoxP3 CGCAGCTCTAGGAGCATGTG 
GATA3 CGGCGTCCATTTTCTTTGGAA 
IL10 GCACACTGTGTCCGAACTC 
IL6 TCAGAGAACTTCCAGGTGAAGA 
LYVE1 GTTCACACACTCCCTGCCTCT 
mKlotho CAGTGTCAGGCAGCTAACAAG 
TNFa CAAAGCATTGCCCATTCGAT 
Ubiq TGTGTCATGTCCGCCCTTCAGTTA 
VEGFA GGCGATTTAGCAGCAGATATAAGAA 
VEGFC TTCAGCCCACACTCCGCTATACAT 
VEGFD TGGCAAGACTTTTGAGCTTCAA   
VEGFR2 AAGTGCATCATCGTTGTTCATA 
VEGFR3 GCTCTTTTTAGATACTGTGGTGAGGAA 
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CHAPTER III 
RESULTS 
 
L-NAME Study 
qPCR and Immunofluorescence Confirm Overexpression Model 
 Quantitative RT-PCR data was obtained for the relative gene expression of VEGF-D for 
confirmation of overexpression for the Kid-VD mice receiving doxycycline. When normalized to 
ubiquitin and wild type murine expression within each experimental group (receiving dox only 
water or water containing both dox and L-NAME), the relative expression for both conditions is 
significantly elevated for the Kid-VD mice (Figure 3). This data confirms the VEGF-D 
overexpression model established in these transgenic mice.  
 
     
Figure 3. Quantitative real-time RT-PCR confirms VEGF-D overexpression model. 
Relative VEGF-D expression of mice positive for KSP-rtTA (red) relative to WT mice (blue) 
with same water treatment. Significant overexpression of VEGF-D in both experimental 
conditions confirms validity of dox-dependent overexpression model used in this study. Mice 
that did not receive L-NAME received 200 mg/mL dox water for four weeks and mice receiving 
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L-NAME were given 200 mg/mL dox only water for one week followed by water having 200 
mg/mL dox and 0.5 mg/mL L-NAME. It should be noted that baseline VEGF-D levels for the L-
NAME cohort were approximately half that of the dox only cohort. Asterisk corresponds to a 
value of statistical significance (*p<0.05,***p<0.001 using a two-tailed students’ T-test with 
unequal variance).  
 
As previously described, murine VEGF-D signaling occurs only through the VEGFR-3 
pathway, which should result in an increase in lymphatic vasculature only. To confirm that the 
increase in signaling expanding the lymphatic vessels rather than simply indicated an increase in 
immune-cell signaling, qPCR analysis was performed for the lymphatic markers LYVE-1 and 
VEGFR-3 (Figure 4). Podoplanin, while often a lymphatic marker, was not used in the qPCR 
analysis because of its constitutive expression by podocytes in the kidney. The increase in both 
LYVE-1 and VEGFR-3 expression supports that the VEGFR-3 signaling that is occurring is 
primarily through the lymphatic vasculature rather than simply the immune cell population 
present, as is expected from the renal lymphatic hyperplasia model. Additionally, the 
overexpressed lymphatic markers indicate that the increase in VEGF-D is not solely due to its 
role as a chemokine.  
19 
 
      
Figure 4. Quantitative real-time RT-PCR confirms lymphatic vessel expansion. Relative 
LYVE-1 and VEGFR-3 expression for mice receiving dox water only (left) and mice receiving 
water supplemented with dox and L-NAME (right). The increase in both of these lymphatic 
markers supports the renal lymphatic hyperplasia model and confirms lymphatic expansion 
rather than solely immune cell signaling.  Asterisk corresponds to a value of statistical 
significance (*p<0.05 using a two-tailed students’ T-test with unequal variance).  
 
Although there are previously published reports that there is no direct change in blood 
endothelium with the VEGFR-3 signaling in the adult.
33
 there have been studies demonstrating 
that renal blood endothelium is potentially VEGFR-3 positive.
36
 Therefore, it is important to rule 
out blood vessel expansion as a factor in our study. To do this, we looked at the relative 
expression of VEGFR-2, VEGF-C, and CD-31 (see Figure 5). VEGFR-2 is a VEGF receptor 
found primarily on blood endothelium that can be signaled by VEGF-C (although VEGF-C is 
primarily lymphangiogenic and signals via VEGFR-3).
33
 The lack of significant change in 
VEGF-C levels confirms the model of inducing lymphangiogenesis is through overexpressing 
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VEGF-D specifically.
33
 VEGFR-2 and CD-31 levels were used to mark any observable blood 
angiogenesis. Their elevated expression requires further investigation, however considering that 
these markers are also expressed to a lesser extent in LECs.
37
 the massive increase in LEC 
numbers observed in the model may be sufficient to explain the overexpression.  
 
  
Figure 5. Slight elevations in endothelial markers can be explained by extreme lymphatic 
overexpression. qPCR expression analysis for primarily endothelial cell markers. Despite some 
change in expression levels, these are less than the approximately 50-fold expression observed 
for lymphatic markers, the expression in these markers can be attributed to the increased 
presence of lymphatics considering that all three of these markers are concurrently expressed on 
lymphatic endothelial cells (though in small quantities). Asterisk corresponds to a value of 
statistical significance (*p<0.05, **p<0.01 using a two-tailed students’ T-test with unequal 
variance).  
 
To further confirm the presence of lymphatic expansion, immunofluorescence was 
performed to observe the morphology of the newly formed lymphatics (see Figure 6). As is 
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easily observed from the images, significant lymphatic expansion occurs for Kid-VD mice 
compared to WT. Future studies need to be conducted to both quantify this expansion and 
determine the functionality of these newly formed vessels. Based on the very limited presence of 
cortical lymphatics in control mice, however, it can be assumed that the lymphatic expansion 
observed is the generation of a new lymphatic network rather than merely dilation or 
hypertrophy of previously present vessels. 
 
 
 
 
  
 
Figure 6. Immunofluorescence demonstrates lymphatic expansion. Images above were taken 
from the renal cortex of WT mice (left) and Kid-VD mice (right). Images were taken at 40X 
magnification, scale bars being 50 µm. (LYVE-1 green, dapi blue). These images 
morphologically demonstrate an expansion of the lymphatic network. (The arrow corresponds to 
a lymphatic vessel, A-arteriole, G-glomerulus). Images reprinted with permission from 
Abouelkheir et al. 2017. 884- 895.
28
  
 
Preliminary Blood Pressure Data Suggest a Protective Effect of Lymphatic Expansion on L-
NAME Induced Hypertension 
To observe the effect of lymphatic expansion on blood pressure, an intersection 
previously published by Mattson et al., systolic blood pressures were measured on a weekly 
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basis for each experimental condition (Figure 7)
38
. Consistently for both groups, Kid-VD mice 
showed a decreased blood pressure from week 2-after those receiving L-NAME had been on the 
treatment for one week. Admittedly, none of the blood pressure values are statistically different. 
Therefore, this study needs to be repeated with a greater sample size to determine if the effect is 
reproducible. Furthermore, negative control mice showed slightly elevated blood pressure 
compared to what is to be expected for a mouse (90-110 mmHg). This could indicate that the 
data is skewed and supports the need for repeated experiments. Additionally, a time course study 
needs to be performed to determine how long it takes for the lymphatic vasculature to expand.  
 
  
Figure 7. Systolic blood pressure measurements suggest a slightly protective effect. Systolic 
blood pressure measurements for WT and Kid-VD mice receiving dox only water or dox water 
followed by dox and L-NAME water (given from week 2). Week 0 measurements were obtained 
immediately prior to starting the study. From week 2 onward, both Kid-VD show a slightly 
protective effect and lowered blood pressure.  
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qPCR Data Show a Slightly Protective Effect in Mice Not Receiving L-NAME in L-NAME 
Induced Hypertension Study 
qPCR analysis was performed for several immune cell populations and inflammation 
markers for both conditions (Figure 8). In the dox-only Kid-VD mice, IL1B, a pro-inflammatory 
marker was significantly decreased, supporting the hypothesis of a protective role of lymphatic 
expansion in instances lacking significant challenge. Moreover, klotho, a protein associated with 
kidney welfare, was significantly elevated in these mice.
39
 Other seemingly elevated or 
decreased values were not statistically significant, however. This could be due to the small 
sample sizes of each group and require the experiment to be repeated to establish reproducibility 
and determine significance.  
24 
 
 
Figure 8. Relative gene expression analysis shows a decrease in pro-inflammatory marker 
IL1B and an increase in protection-associated protein, klotho, in Kid-VD mice. Relative 
gene expression data obtained by qPCR for control and experimental mice receiving dox only 
water (top) and water supplemented with both dox and L-NAME. Relative expression, 
normalized to ubiquitin, shows a decrease in IL1B and an increase in klotho in mice receiving 
only dox water. No significant differences were seen in the mice receiving L-NAME treatment. 
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No statistical test could be performed for IL6 and TNFa. Otherwise, a two-tailed students’ T-test 
with unequal variance was performed to determine statistical significance (*p<0.05, **p<0.01). 
 
Salt-Sensitive Hypertension Study 
qPCR and Immunofluorescence Confirm Overexpression Model 
 Subsequent to sacrificing the cohort of mice suffering from salt-sensitive hypertension, 
qPCR analysis was confirm overexpression model and the presence of lymphatic vessels. After 
normalizing to ubiquitin and the expression of WT mice, results show statistically significant 
overexpression of VEGF-D (Figure 9) and its receptor, VEGFR-3, along with increased 
expression of lymphatic marker, LYVE-1 (Figure 10). The increased expression of LYVE-1 
along with the receptor and its ligand confirm the lymphatic hyperplasia model rather than 
merely increased immune signaling.  
 
  
Figure 9. qPCR analysis of VEGF-D expression confirms overexpression model. Relative 
VEGF-D expression of Kid-VD mice (red) relative to WT mice (blue) with same protocol. 
Significant overexpression of VEGF-D in experimental condition confirms validity of dox-
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dependent overexpression model used in this study. (**p<0.01, using a two-tailed students’ T-
test with unequal variance). 
 
  
Figure 10. qPCR analysis of lymphatic markers confirm overexpression model. Significant 
overexpression of VEGFR-3, the VEGF-D receptor, combined with increased expression of 
lymphatic marker LYVE-1 confirm the lymphatic hyperplasia model. (**p<0.01, using a two-
tailed students’ T-test with unequal variance).  
  
 Once lymphatic hyperplasia was confirmed, the next task was to determine if there was 
any effect on blood angiogenesis. To this effect, qPCR analysis was performed for VEGF-C, 
VEGFR-2, CD31, and VEGF-A. VEGF-C is a VEGF isoform expressed by both blood 
endothelium and lymphatics that signals through VEGFR-2. CD31 is an endothelial marker, and 
VEGF-A is a blood-endothelium specific isoform of VEGF-D. As the relative expression of 
these genes illustrates, (Figure 11) there are only significant increases in VEGR-2 and CD31. 
Considering that VEGFR-2 is also expressed by lymphatic vessels, the VEGFR-2 overexpression 
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can be explained by the expanded lymphatic vasculature. The source of the increased CD31 
expression levels, however, needs to be determined by further experimentation. The expression 
levels of VEGF-C and VEGF-A, however, are comparable to the mice in the study lacking 
VEGF-D overexpression, supporting the utility of the model in its specificity for VEGF-D and 
the conclusion that the increased CD31 levels are likely not due to an increase in overall 
angiogenic program.  
 
 
Figure 11. qPCR analysis of blood vasculature markers is likely not due to expanded blood 
vasculature. qPCR analysis of VEGF-C, VEGFR-2, CD31, and VEGF-A shows significant 
elevation of VEGFR-2 and CD31. Increased VEGFR-2 levels can be explained by the expanded 
lymphatic vasculature while the source of increased CD31 needs to be determined through 
further studies. (**p<0.01, using a two-tailed students’ T-test with unequal variance).  
 
 To morphologically confirm the presence of an expanded lymphatic network, 
immunofluorescence was conducted to mark lymphatic vessels using LYVE-1 (Figure 12). As 
the images depict, mice having the overexpression model have many more LYVE-1 positive 
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structures compared to mice lacking this genetic modification. Expanded lymphatic vasculature 
was most prominent in the cortex. While this serves to confirm the overexpression model, more 
studies need to be conducted to quantify the expansion and determine the functionality of the 
expanded network. These are studies we hope to conduct in the future. The degree of expansion, 
however, is suggestive of de novo lymphangiogenesis rather than a mere expansion of the 
preexisting network. 
 
    
Figure 12. Immunofluorescent histology of + Kid-VD mice shows expanded lymphatic 
network, confirming hyperplasia model. Images were taken from the renal cortex of WT (left) 
and Kid-VD (right) mice. Images were taken at 20X magnification, scale bars being 100 μm. 
(LYVE-1 green, dapi blue, G-glomerulus). 
 
Blood Pressure Data Show + Kid-VD Mice Are Protected Against Severe Blood Pressures in 
Salt-Sensitive Hypertension Study 
 For the majority of the protocol outlined in Table 1 (weeks 2 through 7) the systolic 
blood pressure of the mice was determined using a tail blood pressure cuff ,with VEGF-D 
expression being induced from weeks 3 to 7. When plotted as a function of time, the data 
demonstrate that Kid-VD mice with increased lymphatic density in the kidney exhibit 
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significantly lower blood pressures under high salt challenge (Figure 13).  As previously stated, 
the study would benefit from a time course experiment to determine whether lymphangiogenesis 
prior to, or concurrent with, the onset of hypertension is most beneficial. 
 
 
Figure 13. Systolic blood pressure measurements show protective effect conveyed by renal 
lymphatic hyperplasia. Measurements of systolic blood pressures of mice taken from week 2 of 
the protocol through week 7. The data show significantly decreased blood pressure 
measurements for mice having overexpression phenotype with development of salt-sensitive 
hypertension at week five. 
 
qPCR Analysis of Inflammatory and Immune Cell Markers Shows Unresolved Inflammation  
 After demonstrating a protective effect regarding blood pressure, we sought to confirm 
the protective effect on a molecular level by comparing immune cell and inflammation markers. 
We hypothesized both of these groups to be lower in the Kid-VD mice than the mice lacking the 
genotypic modifications considering that both groups received the hypertension and 
inflammation challenges in the form of the high salt diet-induced salt sensitive hypertension. 
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IL1- β is an inflammatory marker, FGFR-1 is a fibrotic receptor, and increased levels of MCP-1 
and CD11c indicate the presence of specific immune cell populations. As can be observed by the 
relative levels of IL1-β, MCP-1, CD11c, and FGFR1 gene expression in Kid-VD mice are all 
significantly elevated compared to the control mice (Figure 14). These elevated levels indicate 
that the protective effects provided by the expanded lymphatic network regarding blood pressure 
are not directly linked to a reduction in inflammatory and immune cell markers. Further studies 
need to be conducted to mechanistically determine the source of protection observed for 
systemic blood pressure and the cause for increased levels of immune cells and inflammatory 
markers.  
 
 
Figure 14. Positive VEGF-D mice show an elevation in inflammatory markers. qPCR 
analysis shows an elevation in inflammatory marker IL1-β, fibrotic receptor FGFR-1, and MCP-
1 and CD11c bearing immune cells. Elevation indicates unresolved inflammation in the kidney 
compared to negative controls receiving the same dietary protocol. Additionally, chemokine 
CCL-21 (not depicted) showed a relative expression of 162.6 and p-value less than 0.05. 
(**p<0.01, *p<0.05).  
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CHAPTER IV 
CONCLUSION 
 
 Throughout this study, mice with inducible lymphangiogenesis in the kidney were placed 
under different treatment protocols to investigate the effect of renal lymphatic hyperplasia on 
blood pressure regulation. The model used was that characterized by Lammoglia et al.
33
 Rather 
than inducing lymphangiogenesis with a short treatment of concentrated doxycycline as 
described in the study, however, mice in this study were placed on 200 mg/L dox to grow a 
dense lymphatic vasculature over the course of 3-4 weeks.   
In the L-NAME study, mice having renal lymphatic overexpression (along with controls) 
were treated with L-NAME, a nitric oxide inhibitor, to induce hypertension due to the stiffening 
and remodeling of the blood vasculature. qPCR analysis and histology confirmed the 
overexpression model and blood pressure measurements showed a potentially protective effect 
on systemic blood pressure. qPCR analysis of inflammatory and immune cell markers showed a 
slight elevation in immune cell subsets, but did not differ significantly.  
 In the salt-sensitive hypertension study, mice overexpressing renal VEGF-D (along with 
controls) were given L-NAME to cause vessel remodeling, resulting in salt-sensitivity. When 
placed on a 4% NaCl diet, these mice were subjected to salt-sensitive hypertension, which causes 
an inflammation challenge in addition to the blood pressure challenge. Similar to the L-NAME 
only study, qPCR analysis and histology confirmed the VEGF-D overexpression model. Unlike 
the previous study, however, blood pressure measurements were significantly lower in mice 
having overexpression of the renal lymphatics, suggesting a protective phenotype. qPCR 
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analysis, however showed significant increases in inflammatory and immune cell markers 
compared to the control mice.  
 Lymphatic vessels are responsible for maintaining fluid balance throughout the body. The 
primary mechanism by which this is done is by taking up the fluid extravastated from the blood 
vasculature once it has passed into the interstitium. In this manner, the lymphatics clear not only 
fluid, but also immune cells and cytokines found within the tissue. Consequently, the lymphatics 
also regulate inflammatory responses throughout the body.
40
 In light of these know functions of 
the lymphatic system, we expected an expansion of the renal lymphatics to result in decreased 
populations of immune cells (such as CD4+ and CD8+ cells) and pro-inflammatory cytokines 
(such as TNFα) that are known to infiltrate the kidney in hypertensive states.38 Our results show, 
however, that increased renal lymphangiogenesis is associated with increased immune cell and 
cytokine presence, bringing into question the functionality of the newly formed vessels. This is 
especially relevant considering that VEGF-D upregulation typically occurs only in states of 
inflammation. Overexpression in adipose, for example, results in increased infiltration of pro-
inflammatory macrophages.
33
 It is possible therefore, that the suggested increased immune cell 
presence is due to trafficking inefficiency rather than a mere “snapshot” of the immune cells 
present in the pathology. To determine whether this is the case, a study of interstitial fluid 
pressure manipulation effects in the presence of the expanded vasculature would prove 
beneficial.  
In future studies, we plan to characterize the functionality of the expanded lymphatics, 
deduce the mechanism by which the renal lymphatics offer protection against systemic blood 
pressure increases, and determine the downstream effects of the infiltration of particular immune 
cell subsets into the kidney. We hope that, collectively, these inquiries will result in the 
33 
 
development of therapeutic targets for the resolution of hypertension in patients suffering from 
this ever-increasingly present cardiovascular disease.   
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Abstract 
Lymphangiogenesis is a recognized hallmark of inflammatory processes in tissues and organs as 
diverse as the skin, heart, bowel, and airways. In clinical and animal models wherein the 
signaling processes of lymphangiogenesis are manipulated, most studies demonstrate that an 
expanded lymphatic vasculature is necessary for the resolution of inflammation. The 
fundamental roles that lymphatics play in fluid clearance and immune cell trafficking from the 
periphery make these results seemingly obvious as a mechanism of alleviating locally inflamed 
environments: the lymphatics are simply providing a drain. Depending on the tissue site, 
lymphangiogenic mechanism, or induction timeframe, however, evidence shows that 
inflammation-associated lymphangiogenesis (IAL) may worsen the pathology. Recent studies 
have identified lymphatic endothelial cells themselves to be local regulators of immune cell 
activity and its consequential phenotypes – a more active role in inflammation regulation than 
previously thought. Indeed, results focusing on the immunocentric roles of peripheral 
lymphatic function have revealed that the basic drainage task of lymphatic vessels is a complex 
balance of locally processed and transported antigens as well as interstitial cytokine and 
immune cell signaling: an interplay that likely defines the function of IAL. This review will summarize the latest findings on how IAL 
impacts a series of disease states in various tissues in both preclinical models and clinical studies. This discussion will serve to highlight 
some emerging areas of lymphatic research in an attempt to answer the question relevant to an array of scientists and clinicians of 
whether IAL helps to fuel or extinguish inflammation. 
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Impact statement 
Inflammatory progression is present in acute 
and chronic tissue pathologies throughout the 
body. Lymphatic vessels play physiological 
roles relevant to all medical fields as 
important regulators of fluid balance, immune 
cell trafficking, and immune identity. 
Lymphangiogenesis is often concurrent with 
inflammation and can potentially aide or 
worsen disease progression. How new 
lymphatic vessels impact inflammation and by 
which mechanism is an important 
consideration in current and future clinical 
therapies targeting inflammation and/or 
vasculogenesis. This review identifies, across a 
range of tissue-specific pathologies, the 
current understanding of inflammation-
associated lymphangiogenesis in the 
progression or resolution of inflammation. 
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Introduction 
The importance of the lymphatic vasculature and its fundamental roles have often been limited to 
the focus of narrow fields. For vascular biologists and tissue physiologists, lymphatics are part of 
the body’s circulation.1 For cancer researchers and clinicians, lymphatics are a route for 
metastatic cells to spread.
2
 For immunologists, lymphatics carry immune cells, deliver antigens, 
and provide a site for immune cell interactions.
3
 In each of these highlighted areas, 
lymphangiogenesis – the growth of new lymphatic vessels – is a potential mechanism for 
increasing that particular role or function. What has become increasingly appreciated, however, 
is that these roles are highly integrated and lymphatic “function” extends to all aspects of tissue 
homeostasis. The best examples of this integration are presented in instances of acute or chronic 
inflammation wherein lymphatics and lymphangiogenesis play a contextually dependent 
beneficial or detrimental role. To illustrate the importance of lymphatic biology and physiology, 
this review will identify how inflammation-associated lymphangiogenesis (IAL) extinguishes or 
propagates inflammatory progression in multiple tissues and diseases.  
Lymphatic vessel and endothelial cell purpose 
Lymphatic endothelial cell (LEC) biology and lymphangiogenesis have been extensively 
examined in a host of excellent reviews in the past decade (see the literature
4-7
). To understand 
how IAL specifically impacts the inflammatory progression, only a brief and basic summary of 
lymphatic roles and lymphatic biology is necessary. The smallest lymphatic vessels, lymphatic 
capillaries, reside in nearly all vascularized tissues as the low pressure sink to which extravasated 
fluid from blood vessels is removed from the interstitium.
1 
This interstitial fluid, or what 
becomes primary lymph, contains all transportable macromolecules of the tissue. This cocktail is 
then intrinsically and extrinsically pumped along larger collecting lymphatic vessels to sentinel 
lymph nodes and is returned to blood circulation further downstream.
8 
Disruption of the 
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lymphatics anywhere along this path by genetic manipulation or surgical resection results in 
peripheral lymphedema.
9 
Consequently, fluid balance, and the resulting biomechanical and 
biochemical environment regulated by flow, is viewed as the predominant lymphatic role. 
Lymphatics also serve as a conduit for immune cell trafficking from the periphery by providing a 
route to the regional lymph nodes. The macromolecules transported via this path include 
cytokines, tissue fragments, hormones, and foreign antigens essential for both regular immune 
maintenance – tissue tolerance – and acquired immune responses.3 The role of ‘‘fluid balance’’ is 
therefore more complex considering that disruption of flow impacts interstitial transport and that 
the composition of the fluid and the immune cells that traffic this route are both responsible for 
the classical lymphatic role in immune regulation. As a result, in instances of lymphatic 
malfunction such as lymphedema, many processes are disrupted: hydrostatic fluid balance is 
altered, cells do not experience interstitial flow, immune cells fail to properly traffic, and 
peripheral antigen transport is significantly delayed. The result: failure of both acute and chronic 
immune responses.
9–11 
Recently, more active roles for LECs in immune regulation have been 
receiving more attention.
12–14 
As was eloquently reviewed by Card et al.,
3 
LECs have the ability 
to themselves take up and process antigens, alter immune cell phenotype and function, serve as a 
site of immune cell interaction, and secrete cytokines that propagate immune responses both 
locally and in the downstream node. These three roles of fluid balance, antigen and immune cell 
clearance, and immune response regulation are therefore not fully distinct. In reality, these 
functions are intimately linked and conceptually important in understanding how lymphatic 
vessels and the extent of IAL induce beneficence or harm. 
Lymphangiogenesis regulation 
Lymphangiogenesis is the development of the initial lymphatic vasculature, the growth of new 
vessels, and the hyperplasia of existing structures. Adult lymphangiogenesis is limited to acute 
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and chronic conditions of inflammation and tissue remodeling.
15 
Adult lymphatic vessels are 
otherwise quiescent explaining the lack of a lymphatic vascular phenotype upon genetic ablation 
of the predominant lymphatic growth factor, vascular endothelial growth factor (VEGF)-C in 
adult mice.
16 
The mechanism by which lymphangiogenesis occurs, most notably the cell source 
of new LECs, has recently been described to be much more complex than the traditional vascular 
sprouting described in blood angiogenesis and is very much tissue specific.
16–20 
Multiple cell 
types may participate or assist in lymphangiogenesis as a source of lymphatic growth factors that 
induce LEC proliferation
6,15 
and equally many antiproliferative cells and cytokines have been 
described.
15,21 
The predominant and consistently key signaling mechanism for 
lymphangiogenesis is VEGF receptor (VEGFR)-3 activation by its ligands VEGF-C and VEGF-
D.
4,7 
LEC VEGFR-3 signaling is requisite in developmental and adult models of 
lymphangiogenesis.
5,22 
Serum levels of VEGF-C and VEGF-D are elevated in inflammatory 
disease further confirming a driving role in IAL.
23–25 
Focusing on VEGFR-3 signaling perhaps 
oversimplifies the mechanisms of IAL in which truly a host of pro- and antifactors are spatially 
and temporally at play; however, VEGFR-3 signaling is the gold standard for targeting lymphatic 
growth in preclinical studies and is now being manipulated in clinical approaches seeking to 
induce or resolve IAL. 
Defining IAL 
Lymphatic vessel roles make the system of increasing interest to the broader scientific 
community. Pathology slides are now routinely labeled for lymphatic protein markers LYVE1 or 
podoplanin by clinical and research labs alike and have identified changes to lymphatic size and 
density across a range of diseases. As previously mentioned, adult lymphangiogenesis is limited 
to states of acute or chronic tissue inflammation (or wound healing which we do not specifically 
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cover herein
26,27
). Most often, this inflammation and the consequences of the resulting IAL are 
dependent upon the tissue in which the remodeling is occurring. For this purpose, we accept IAL 
to be either expansion or generation of lymphatic capillary networks or the destabilization and 
hyperplasia of larger vessels. Thus, while lymphangiogenesis should increase fluid clearance, it 
is noted in multiple cases presented herein that IAL may merely result in expanded but less 
functional lymphatics. This review will highlight specific tissue pathologies in an attempt to give 
a broad overview of the contextually dependent beneficial and detrimental effects of IAL. Two 
well-studied IAL manifestations that are not necessarily limited to a particular region of the 
body, lymph node expansion and peritumoral lymphangiogenesis, are easily illustrated 
environments that provide an excellent basis to define potential roles of IAL and pathological 
lymphatic functions prior to discussing tissue-specific effects. 
Inflammatory lymph node remodeling 
Lymph node remodeling in response to afferent peripheral inflammation is a well-characterized 
process. Changes in the lymph node environment can include volume expansion from increased 
fluid burden, expansion of the LECstructured lymphatic sinuses, expansion of the fibroblastic 
reticular cell network, and proliferation of lymphocyte populations.
15 
These changes are 
mechanically mediated and driven by vascular growth factors, cytokines, and CCL21-expressing 
T-cells entering with the afferent lymph as well as by lymph node reticular fibroblasts and B-
cells (and later by neutrophils).
15 
CCL21 is a noted LEC-secreted chemokine that guides 
leukocytes to lymphatic vessels for tissue egress; its levels are indicative in this review of both 
LEC numbers and activation.
5 
Induction of proper lymph node expansion is a necessary part of 
resolving afferent inflammation and is documented in most IAL models in this review.
28 
Once 
the peripheral inflammation is resolved, lymph node volumes recede and lymphatic structures 
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regress, a process driven at least in part by changes in the T-cell secretome.
29,30 
Nodal expansion 
and subsequent resolution are thus a beneficial model by which to judge IAL. 
Lessons from cancer research 
Increased tumor-associated lymphatic vessel density and sentinel lymph node expansion 
correlate with higher incidences of metastases and poorer survival statistics in multiple cancer 
forms.
31–33 
Lymphatic expansion by VEGF-C- or VEGF-D-expressing tumors is overall 
detrimental to patients, leading to dilation and hyperplasia of lymphatic vasculature,
2,34 
increased 
lymph flow,
35,36 
and increased lymphatic metastases.
2,37 
One beneficial consequence of this 
process is that future therapies could potentially target the tumor spread via the upstream 
lymphatic network: a novel strategy of prevention and treatment of metastatic lymph nodes that 
shows promise in preclinical models.
38
 
Tumor-associated lymphatics are, however, more than a metastatic highway. When tumors 
form, one component promoting their rapid progression is the ability to hijack immune signaling 
pathways.
39–41 This mimicry effect prohibits the host’s innate immune response by activating 
more regulatory T-cells and preventing them from functioning against cancer cells, leading to 
tumor tolerance of the host’s immune defenses.39–41 Metastatic tumors are also known to secrete 
the leukocyte attractant CCL21,
42 
a chemokine highly expressed by LECs, that serves to 
propagate leukocyte-driven lymphangiogenesis and essentially makes the tumor a rogue tertiary 
lymphoid organ (TLO).
43 
The increased local LEC-immune interaction is essential for 
immunotolerance and the tumor’s ability to evade normal immune responses.43–46 Considering 
that the roles of lymphatics in tumor progression involve both local fluid and immune regulation, 
their effects serve as a model for understanding the impact of IAL on other disease states. 
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IAL in tissue inflammation pathologies 
Immunohistochemical labeling has identified lymphatic vessels in most tissues – recent 
appreciation of functional lymphatics in the eye and brain only highlight the system’s 
potential
47,48 – and a multitude of case reports identify increased or expanded lymphatic vessels 
with inflammation. For many tissues, a more complete characterization of lymphangiogenesis 
and, in most cases, direct evidence of the benefits or harm of IAL through the application of 
VEGFR-3 ligands (genetically, ectopically, or virally) or blockade of this pathway, is covered in 
multiple pathologies. In others, we cite literature wherein lymphatics themselves or lymphatic 
roles are referenced in the disease and extrapolate how changes in lymphatic density might 
impact tissue disease state. 
Lymphangiogenesis in airway inflammation 
Airway lymphatic vessels are necessary to regulate immune responses to the external 
environment and maintain fluid balance in the respiratory mucosa. Inhaled pathogens, including 
air pollution particles,
49 
are transported via lymph to downstream lymph nodes for immune 
surveillance. Rodent models using Mycoplasma pulmonis infection have offered great insight 
into the mechanisms and function of IAL in the lung and airways.
50 
Infection results in robust 
VEGFR-3 signaling and B- and T-lymphocyte-dependent lymphatic expansion that persists even 
after resolution of the infection.
51,52 
While these lymphatics were morphologically different than 
native vessels (suggestive of altered function
53
), blocking IAL during infection results in 
increased mucosal edema.
51 
Conversely, VEGF-C-induction of severe pulmonary 
lymphangiectasia, a condition of monstrous lymphatic expansion, also increased lung edema,
54 
demonstrating that the quality of these newly developed vessels dictates their beneficence. 
Mycobacterium tuberculosis-induced granulomas also increase VEGF-C expression, resulting in 
local IAL.
55 
Tuberculosis highlights active immune roles of LECs, with nodal IAL being 
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requisite for both antigen-specific T-cell responses
55 
and, interestingly, the ability of M. 
tuberculosis to directly infect LECs for the purpose of proliferation.
56 
In allergic rhinitis or 
asthma models, neither lymphangiogenesis nor vascular remodeling is consistently 
demonstrated.
57,58 
Changes to lymphatic morphology have been reported in chronic obstructive 
pulmonary disease and could play a role in sustaining or priming inflammation, though no 
systematic study has yet been made of lymphatic changes.
59 
What role bronchiolar lymphatic 
density plays in chronic asthma, obstructive pulmonary diseases, or how IAL impacts later 
responses to allergens or infection is not entirely clear. 
Lymphangioleiomyomatosis (LAM) is systemic cystic disease but is often initially diagnosed 
through its pulmonary implications that include chylothorax (lymphatic, not hemal, fluid 
leakage). LAM pulmonary cysts are characterized by local IAL and massively elevated serum 
VEGF-D levels – 2- to 10-fold higher than healthy patients – may serve as a biomarker for the 
condition.
23,60 
Human samples from other respiratory diseases such as pulmonary fibrosis and 
pneumonia samples have shown increased lymphatic density, lymphoid follicles, and elevated 
LEC-associated CCL21–CCR7 signaling.61 Whether lymphatics serve as LAM sites and what 
role VEGF-D-mediated IAL plays in LAM and other lung pathologies remains to be elucidated. 
Dermal inflammation and lymphangiogenesis 
In the skin, IAL and changes to lymphatic patterning have been identified in both chronic
62 
and 
acute
63 
inflammatory skin disorders including psoriasis, atopic dermatitis, and systemic 
sclerosis.
62 
Altered dermal lymphatics are also involved in dermal sodium balance
64 
and tolerance 
sensitization.
11
 
Acute dermal UVB-induced inflammation is characterized by enlarged lymphatic vessels and 
increased permeability leading to expanded inflammation and dermal edema.
63,65 
Blocking 
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VEGFR-3, inhibiting lymphatic expansion, prolonged tissue swelling, and VEGF-C 
overexpression attenuated fluid accumulation through increased lymphatic vessel density.
63,66 
While these models are well characterized, conditions such as atopic dermatitis and urticaria 
have also been correlated with vasculogenic factors, such as VEGF and semaphorins, that 
suggest a role for lymphangiogenesis in each disease.
62 
In samples of human skin with psoriasis, 
the lymphatic vessels were enlarged,
67–69 
VEGF-C was highly overexpressed, and skin mast cell 
numbers were elevated.
67–70 
In acute mouse models, limiting IAL by inhibition of VEGFR-3 
signaling increased inflammation and the infiltration, but presumably not the exit, of CD11bþ 
immune cells.
71 
Conversely, overexpression of VEGF-C led to increased lymphangiogenesis and 
an overall reduction in chronic skin inflammation.
71,72 
Consequently, in chronic skin disease 
models, lymphangiogenesis appears to inhibit or resolve inflammation. 
Additionally, IAL has been implicated in contact hypersensitivity. K14-VEGFR-3-Ig 
transgenic mice lack dermal lymphatic vessels and have decreased solute transport and dendritic 
cell migration to the draining lymph nodes.
11 
These mice showed greater swelling upon initial 
contact hypersensitization – demonstrating the importance of the lymphatic vessels in dermal 
fluid balance – but failed to tolerize to hypersensitization upon further challenge.11 While these 
mice could elicit robust T-cell responses to dermal immunizations, the response was delayed and, 
with age, these mice developed autoantibodies to dermal proteins.
11 
These studies demonstrate 
that healthy lymphatic transport is necessary for maintaining long-term immune tolerance. 
Not only does lymphatic density play a role in inflammatory skin diseases, but they have also 
been implicated in homeostatic and blood pressure regulatory control systems in dermal 
cutaneous tissue.
64 
Salt-sensitive individuals store excess electrolytes (Na+ and Cl-) in the skin 
interstitium that ultimately induce increased VEGF-C expression from infiltrating macrophages 
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and, consequently, lymphangiogenesis. In turn, the excess electrolytes are cleared by these new 
lymphatics.
64 
Studies have also shown, however, that deletion of TonEBP (tonicity-responsive 
enhancer binding protein) from monocytes led to a lack of VEGF-C secretion, decreased 
clearance of electrolytes, and increased blood pressure.
64 
Wiig et al. confirmed this effect by also 
inhibiting VEGFR-3, thereby decreasing cutaneous lymphatic vessel density and inducing 
hypertension by preventing sufficient clearance of excess electrolytes. VEGF-C overexpression 
had the opposite effect, increasing the uptake of electrolytes and water in the skin to further 
confirm the homeostatic role of dermal lymphatic remodeling.
64
 
Lymphangiogenesis in intestinal inflammation 
Gut lymphatics are not only responsible for surveying the massive bacterial load of the intestinal 
lumen, and the immunologic and inflammatory maintenance of such, but also play a lymphatic 
role that has not yet been touched upon: that of dietary lipid absorption in the intestine. Intestinal 
enterocytes take up digested and emulsified long chain dietary fatty acids from the lumen and 
repackage the fats into chylomicrons and very low-density lipoprotein particles that enter the 
initial lymphatic lacteal found within each villus. This chyle-rich lymph is transported through 
the submucosal lymphatics, large conducting mesenteric lymphatic vessels, and eventually on to 
the blood circulation at the thoracic duct. VEGFR-3-mediated deficiencies in the structure and 
maintenance of the lacteals disrupt lipid absorption, while changes in diet and hydration 
primarily affect mesenteric lymph flow rates.
73 
Genetic and inflammatory alterations of 
lymphatic architecture result in lymph leakage.
74 
Lymph leaked into the peritoneum is rich in 
soluble antigens and lipophilic bacterial products (e.g. lipopolysaccharide), and hence initiates 
the inflammatory immune cascade of macrophage and dendritic cell activation: a cycle of 
inflammation that likely further alters lymphatic function.
74,75 
Lymph leaked in the mesentery is 
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also fatty acid-rich and highly adipogenic, causing expansion of the adipose tissue surrounding 
the collecting mesenteric 
vessels.74,76 
In chronic inflammatory bowel diseases from ulcerative colitis to Crohn’s disease, lacteals 
dilate, submucosal edema occurs, and initial lymphatic capillaries proliferate.
73 
It appears to be 
unlikely that IAL improves lymphatic drainage function under these conditions that manifest 
with rampant edema and failure of dendritic cells to migrate from the tissue,
77 
but this may be 
partially caused by downstream reductions in pumping or lymphatic obstructions with 
lymphangitis.
73,78 In Crohn’s mesenteric tissue biopsies, granulomatous lymphangitis further 
propagates inflammation as CD20þ B-cell rich TLOs reside along the mesenteric lymphatic 
vessels inhibiting flow and likely modulating the local immune response.
78 As in Crohn’s, animal 
models of ileitis and colitis also exhibit lymphangiogenesis in the lymph nodes and lymphatic-
associated TLOs, in addition to defective lymphatic drainage andpumping, as well as sustained 
mucosal edema and inflammation.
79,80 Expansion of the mesenteric adipose tissue, termed ‘‘fat-
wrapping’’ or ‘‘creepingfat,’’ isa hallmark of Crohn’s.Poorlymphaticfunction, accompanied by 
leaking mesenteric lymph and coupled with increased cytokine accumulation from the 
surrounding inflamed tissue, creates an adipogenic environment similar to that in well-
characterized peripheral lymphedema models.
73,81,82 
Conversely, mouse models with congenital 
intestinal lymphatic dysplasia or targeted deletion of LECs both exhibit increased intestinal 
inflammation.
21 
Blockade of IAL using an antibody against VEGFR-3 has also led to increased 
leukocyte accumulation and edema in a spontaneous mouse irritable bowel disease model.
83 
Destabilization of the existing lymphatic vasculature thus reduces the critical maintenance roles 
of gut lymphatics suggesting that IAL factors are overall detrimental to bowel diseases. 
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Lymphangiogenesis in cardiovascular disease 
In addition to lymphatics being part of the body’s greater circulatory loop, local lymphatics are 
critical in maintaining the health of the cardiovascular system. The lymphatic vasculature is 
particularly extensive within the heart and near the region of the vena cava, where lymphatic 
fluid is eventually returned to blood circulation.
1 
Recently, myocardial infarctions (MI), an all-
too-common cardiac pathology, have been identified as an inflammation-associated event with 
lymphatics playing a significant healing role. Post-MI inflammation is accompanied by increased 
VEGFR-3 signaling and lymphangiogenesis, particularly at the border of the scarred/infarct 
region.
17 
Furthermore, VEGF-C administration after a myocardial infarct event induces 
lymphangiogenesis, improves cardiac function, and increases the drainage of the non-infarct 
region thereby improving prognosis.
17,84 
Recently, delivery of adenoviral VEGF-D has also 
demonstrated improvement in cardiac function and is currently progressing to the clinic for 
further study. This work promisingly links cardiac lymphangiogenesis to improved patient health 
and future clinical 
practice.85,86 
Atherosclerosis is characterized by a buildup of cholesterol plaques in arterial walls.
87 
Local 
lymphatic expansion (or lack thereof) and immune cell trafficking have been named key players 
in the inflammatory aspect of this disease.
88 
One characteristic of the pathology is the conversion 
of macrophages to foam cells by the ingestion of lipids in the plaque and their inability to exit the 
tissue in the absence of lymphatic vessels.
89,90 
Lymphatic vessels may also provide a route to 
clear cholesterol from the atherosclerotic lesion via reverse cholesterol transport (RCT). RCT is 
the process by which cholesterol is taken up by high-density lipoprotein (HDL) in the periphery 
and transported to the liver for processing and degradation.
91,92 
Recent studies have implicated 
the lymphatics as the primary transport system by which peripheral HDL enters circulation.
91,93 
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Lymphatic density may thus control the rate of tissue cholesterol clearance; several animal 
studies have demonstrated a disruption in RCT with a disruption of lymphatic vessels.
91,93 
Lymphatics have also been implicated in venous health, with lymphatic ligation increasing 
venous lipid retention and TNF-alpha-mediated degeneration.
94 
Martel et al.
93 
also confirmed 
significantly impaired cholesterol removal from transplanted atherosclerotic aortas in which 
VEGFR-3 had been blocked. Mice with inherently reduced lymphatic density and impaired 
VEGFR-3 signaling also demonstrate increased atherosclerotic phenotypes.
95 
It should be noted 
that the role of the lymphatics in this process is potentially one of local immune regulation or 
even active HDL transport from the tissue space by LECs themselves.
91 
Collectively, the 
presence of lymphatic vessels and lymphangiogenesis appears to be beneficial in conditions of 
atherosclerosis. As such, increasing lymphangiogenesis at an atherosclerotic site could prove to 
be therapeutic in the clinic. 
Considering their close association with arterial walls, it is reasonable to ponder whether 
lymphatics play a role in vascular inflammation, venous disease, and hypertension. We have 
already discussed how dermal lymphatics play a role in sodium storage and, hence, potentially 
salt-sensitive hypertension.
96 
In other organ systems, lymphatic function may locally regulate 
endocrine tissue homeostasis and their hormone secretion and transport, such as the renin–
angiotensin–aldosterone system present in the kidney.97 Recent work in the kidney, for example, 
has implicated changes in renal T-cell populations and inflammation with hypertension in both 
human samples and animal models.
98 
With the lymphatics regulating immune phenotypes, tissue 
inflammation, cholesterol transport, and salt retention, lymphangiogenesis potentially plays 
complex and multitudinous roles in regulating cardiovascular health. 
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Lymphangiogenesis and renal disease 
The field of renal health and kidney inflammation more specifically is associated with conditions 
such as hypertension, diabetes, and proteinuria.
99 
Little is published about the physiological 
functions of renal lymphatics, and less so in these disease states. In animal models, ligation of 
renal lymphatics results in renal edema, increased urine volume, and hypertension.
100,101 
Two 
case reports describing patients presenting with hypertension have diagnosed concurrent renal 
lymphangiectasia. In these cases, hypertension is attributed to the mechanical stress applied by 
hyperplastic collecting lymphatic vessels.
102,103 
In one case study, the hypertension was resolved 
upon removal of the collected fluid, while in another the patient’s hypertension was resolved 
with angiotensin-converting enzyme inhibitors, pain medication, and salt restriction.
102,103 
Lymphatic function in immune cell trafficking may present a clearer role: increased T-cell 
infiltration is necessary for development of Dahl salt-sensitive hypertension via aberrant 
activation of the renin–angiotensin system in rats.104–106 While inflammatory immune cells are a 
source of VEGFR-3 ligands, none of these studies directly implicate IAL, or a lack thereof, to 
hypertension specifically. We recently presented a model of VEGF-D-driven expansion of the 
renal lymphatic vasculature (Figure 1) that could potentially be used to assess how lymphatic 
function impacts blood pressure in a variety of hypertensive models.
107 
Based on the results in 
other tissues, inducing renal lymphangiogenesis may alleviate the kidney’s inflammatory burden 
and increase immune cell egress in these models. 
Renal diseases often manifest with concurrent inflammation, fibrosis, and proteinuria. 
Proteinuria is not only a symptom but also directly damages tubular epithelia resulting in pro-
inflammatory CC- and CXC-chemokine secretions.
108 
These chemokines also promote the 
recruitment of circulating leukocytes, such as regulatory T-cells, and therefore, indirectly 
promote IAL.
109 
Lymphangiogenesis has also been previously correlated with renal fibrosis in 
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several studies.
110–113 
Renal lymphangiogenesis has been identified, however, prior to the 
development of marked fibrosis.
114 
Blocking CCL21, a LEC-secreted chemokine, reduces kidney 
fibrosis by preventing the infiltration of fibrocytes and macrophages.
115 
Together, these 
evidences suggest IAL occurs early with proteinuria and is potentially necessary, or merely an 
early indicator of, the development of subsequent fibrotic phenotypes. In contrast to other IAL 
events, lymphangiogenesis could be targeted to prevent proteinuria-mediated tubulointerstitial 
fibrosis; however, chronic lymphatic ligation worsens renal inflammation, fibrosis, and 
proteinuria
100 
so disruption of homeostatic lymphatic function may have severe consequences. 
 
endothelial growth factor-D 
In healthy kidneys lacking any sort of pathology, relatively few lymphatic capillaries are 
present within the cortex of the kidney.
99 
Despite their relative scarcity, their chronic ligation is 
severely detrimental to renal function and inflammation.
100 
Chronic inflammatory conditions 
such as lupus nephritis, antineutrophil cytoplasmic antibody-related glomerulonephritis, 
tubulointerstitial nephritis, and IgA nephropathy show markedly increased populations of 
lymphatic vessels in the renal cortex compared to controls.
111 
Additionally, Type 2 diabetic 
nephropathy biopsies have shown both increased VEGF-C expression and elevated lymphatic 
 
Figure 1 Expansion of the renal lymphatic network. Lymphatic vessels are few in the murine renal cortex limited to tracking a long interlobular arterioles (arrow, left). 
Overexpression of VEGF-D (right) by tubular epithelial cells induces a massive expansion of cortical lymphatic vessels (green, LYVE-1) providing a model to study the 
impact of lymphatic density in renal function and pathology. ‘‘A’’ indicates arteriole. ‘‘G’’ indicate glomeruli. Blue ¼ DAPI. Scale bars ¼ 50 mm. VEGF-D: vascular 
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density.
111 
A study focusing specifically on tubulointerstitial nephritis found that the number of 
lymphatic vessels was significantly correlated with the degree of fibrosis and that infiltrating 
monocytes were expressing VEGF-C.
111 
Biopsies taken from chronic interstitial nephritis or 
chronic IgA nephropathy patients showed significantly elevated lymphatic density compared to 
biopsies of acute tubulointerstitial nephropathy patients.
116 
These results suggest that sustained 
inflammation must be present for a substantial period of time prior to (or to initiate) 
lymphangiogenesis. Whether lymphatic expansion is actively involved or merely a marker of 
these pathologies, however, remains to be determined, though it is intriguing to speculate that by 
having fewer lymphatics when healthy, the kidney is ripe for IAL causing dysfunction. 
Adipose tissue, the metabolic syndrome, and lymphatic function 
Systemic manifestations of the metabolic syndrome – hyperlipidemia, hyperglycemia, and 
insulin resistance – all have their root in dysfunctional obese adipose tissue that is characterized 
by inadequate vascularization and increased fibrosis and inflammation.
117 
In mouse models 
targeting inflammation, either by reducing immune cell populations in adipose tissue or by 
genetic manipulation of inflammatory cytokines, systemic metabolism is improved.
118 
What role 
lymphatic vessels play in regulating the adipose tissue interstitium is still unknown in normal 
physiology, but feedback between the lymphatics and adipocytes is clear. Adipose tissue 
hormones, collectively adipokines, have potent effects on endothelial cell biology.
76 
Adiponectin, 
for example, increases nitric oxide synthase in LECs and adiponectin treatment aides in 
ameliorating lymphedema.
119 
How other adipokines, such as leptin, impact LEC biology and 
function is also of timely interest in many research groups.
120 
Multiple mouse models targeting 
lymphatic vessel development and maturation demonstrate increased adiposity accompanied by 
adult onset obesity.
76 
In lymphedema, when lymph flow is compromised, potentially massive 
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adipose expansion occurs in the affected periphery.
121 
In inflammation, leaky lymphatics driven 
by IAL factors are commiserate with expansion of the adipose directly around the destabilized 
lymphatic vessel. Inflammation models have also demonstrated local and lymph node adiposity 
with IAL.
73 
Adipose–lymphatic interactions are not all malicious, however, as perinodal adipose 
tissue and adipose-resident monocytes along collecting lymphatic vessels play an important role 
in maintaining lymph node and immune surveillance functions, 
respectively.
73,75
 
Measurements of lymph flow in generalized obesity demonstrate reduced lymphatic function, 
and its improvement with weight loss and exercise in the same animals.
122,123 
In lipedema, a 
condition of pathologic adipogenesis, lymphatic function is reduced and potentially plays a role 
in disease progression.
15 
A multitude of adipokines and growth factors are expressed in healthy 
and obese adipose and their relative distributions may impact local lymphatic integrity and 
function as well as IAL.
76 
VEGFC and VEGF-D are heightened in obesity; a recent study of 
systemic VEGFR-3 blockade improved glucose regulation in part through reduced adipose tissue 
macrophage infiltration.
24 
Similarly, mice with constitutive dermal overexpression of VEGF-C 
exhibit hyperplastic lymphatic vessels, heightened adipose inflammation, and increased adiposity 
and insulin resistance.
124 
Recently, we developed a mouse model with inducible adipocyte- 
specific overexpression of VEGF-D and, while the mice demonstrated a massive expansion of 
lymphatic networks in adipose tissues, macrophage recruitment and inflammation were also 
increased.
107 
With high fat diet feeding that normally drives adipose tissue inflammation, fewer 
resident macrophages were found with increased lymphatic density (Figure 2). Uncoupling the 
negative chemokine aspects of these lymphatic growth factors from the potentially positive 
effects of increased lymphatic density is currently underway.  
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D: vascular endothelial growth factor-D 
Though adipose inflammation may be a target for lymphangiogenesis in the metabolic 
syndrome, diabetic lymphatic function, or, perhaps more importantly, direct lymphangiogenic 
effects on beta cells’ insulin secretion and the pancreatic islets is less clear. Islets have intra-islet 
blood capillaries, but lymphatic capillaries are only found in the islet periphery. In two models in 
which VEGF-C or VEGF-D was directly overexpressed in beta cells, no lymphatic ingrowth to 
the islets was observed, despite marked extra-islet lymphatic expansion.
34,125 
In the commonly 
used model of streptozotocin (STZ)-induced islet toxicity, IAL was identified around the 
islets.
126 
Inhibiting IAL in the STZ model by blocking VEGFR-3 reduced islet cytokine levels as 
well as macrophage infiltration and preserved islet mass (and, by extension, insulin secretion).
126 
Whether islet IAL is good or bad may therefore depend on the underlying mechanism of beta cell 
loss, i.e. Type 1 versus Type 2 diabetes. No large-scale systematic study in humans has yet 
identified peripheral lymphatics to be functionally altered in diabetes, but in some patient 
samples and murine models, insulin resistance and obesity, not high fat diet alone, reduces 
lymphatic fluid transport.
127,128 
Since weight loss and exercise alone each rapidly improve 
obesity-associated lymphatic dysfunction,
123,127 
are lymphatic deficiencies merely reflective of 
greater tissue imbalance? The importance of lymphangiogenesis and LECs in modulating 
 
Figure 2 Adipose tissue lymphangiogenesis. Obese murine inguinal adipose tissue lacks lymphatic capillaries (green, LYVE1) and contains macrophages formed crown-
like structures (red, Mac2; arrows highlight some) in the inflamed tissue (left). VEGF-D overexpression induces lymphangiogenesis in adipose tissue (right), with IAL 
potentially providing a route for immune efflux with fewer Mac2þ areas (arrows, all noted) in equally obese adipose tissue. Blue ¼ DAPI. Scale bars ¼ 100 mm. VEGF- 
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peripheral inflammation, however, still makes lymphatic expansion an attractive potential target 
in dysfunctional adipose tissue in obesity, lipedema, and lymphedema and in the peripheral 
vascular manifestations of diabetes. 
IAL in female reproductive tissues 
Lymphangiogenesis occurs in the ovaries and uterus with reproductive cycles and 
pregnancy
26,129
; however, inflammatory diseases of the female reproductive tissues are largely 
understudied and few murine models exist to recapitulate them. Endometriosis is a disease 
uniquely affecting women in which tissue resembling the uterine lining – the endometrium – is 
found in tissue outside the uterus, as far away as the lungs.
130 
One explanation is similar to the 
theory of LAM lesion spreading: that shed endometrial tissue and cells are transported via the 
lymphatic system to other regions of the body causing lesions at ectopic sites.
131 
Reichelt et al.
132 
demonstrated an increase in the lymphatic density of peritoneal lesions compared to normal 
peritoneum. In one study, VEGF-C and VEGF-D were both found to be significantly upregulated 
in endometriotic lesions and accompanied by significant lymphangiogenesis (and minimal blood 
angiogenesis) in ectopic lesions.
132 
Endometriosis is at least partially a chronic inflammatory 
disease, in which the inflammation is perpetuated, rather than resolved, by the 
lymphangiogenesis.
132 
Further work beyond male mouse models may identify what roles 
lymphatics play in endometriosis and other diseases of women’s health. 
Transplantation neovascularization 
One area where the role of lymphatics is often emphasized is in the context of tissue transplants. 
Transplant outcomes demonstrate the range of responses associated with IAL as often a mixture 
of harm and benefit depending on the context. In cardiac allografts, most often, 
lymphangiogenesis increases the chances of rejection, with blockage of VEGFR-3 signaling 
improving the outcome of the allograft.
133 
This result is likely due to the decrease in CCL21 
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expression and CD8þ T-cell (lymphocytes that regulate tolerance) infiltration upon blocking 
VEGFR-3.
133 
Another common transplant highlighting a potentially negative role of the 
lymphatics is that of corneal transplants. In instances of both human and animal keteroplasties, 
corneal lymphangiogenesis decreases the graft’s survival and is an indication of impending 
rejection.
134–137 
Several studies show that antivascular treatment both pre- and postprocedure 
improve the chances of corneal graft survival.
136,138,139
 
 
 
The effect of IAL in renal transplants, however, is more ambiguous. In the three weeks 
following kidney transplant, the donor organ generates a new lymphatic system.
140 
This process 
 
Figure 3 Inflammation-associated lymphangiogenesis (IAL) and the modulation of tissue homeostasis. Normal, functional lymphatics clear fluid, macromolecules, 
and immune cells – both passively and actively – from the peripheral interstitium. Trafficking to the afferent lymph node allows for the propagation of specific  
immune responses. When lymphatics are deficient (left), as in lymphedema, failed clearance leads to chronic inflammation. With IAL in inflammation, an increased 
functional lymphatic network permits resolution as fluid and cytokines are cleared and leukocytes – activated locally by inflammation or through contact with 
lymphatic endothelial cells (LEC) – traffic to the lymph node. Disorganized lymphatic expansion in inflammation, however, results in lymph efflux, or ‘‘leakiness ’’ of 
hyperplastic vessel (right).This reduced functional capacity fails to aid, and indeed can propagate, inflammation 
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is crucial, and low lymphatic density in the first postprocedural biopsy has been correlated with 
acute transplant rejection.
141 
This is likely due to the role of the lymphatics in fluid clearance, 
inflammation modulation, and immune cell clearance after the operation.
142 
Once the initial IAL 
takes place, however, persistent lymphangiogenesis and increased lymphatic density in regions 
of inflammation have been associated with transplant rejection.
141 
Whether the continuing 
lymphangiogenesis is merely a marker or a cause of rejection is currently unknown. One possible 
explanation is that, after achieving homeostatic fluid balance, the increased presence of 
lymphatics allows antigenpresenting cells to induce an allogenic response as in the cornea.
142 
As 
more is understood about the evolution and functions of these vessels following transplant, 
however, more specific therapies can be designed to improve the chances of allograft survival. 
Conclusion 
No region of the body is impenetrable to the flames of inflammation. The body’s natural 
response to tissue injury is inflammation, often accompanied with lymphangiogenesis, that is a 
required part of healing. This IAL and its associated responses, much like fire itself, can be 
classified into a few broad categories: absent, functional, and dysfunctional (Figure 3). In 
instances when IAL results in the development of functional vasculature, it serves its purpose of 
fluid and macromolecule reclamation and immune cell modulation and clearance resulting in 
restoration to a preinflammatory state. In this way, IAL performs its physiological duties similar 
to a beneficial fire that is extinguished when needed. Much like a wildfire, however, left to 
progress unchecked, IAL results in poorly functional vessels, a worsened immunologic state, and 
unresolved inflammation. As a result, the simple question of whether IAL is beneficial or 
harmful receives the unsatisfying answer of: it depends. Lymphatics are at the center in the 
interplay of fluid clearance, inflammatory cytokine removal, and innate and acquired immune 
regulation. Understanding IAL and its degree of beneficence on a disease- and tissue-basis is 
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requisite in determining whether lymphangiogenesis will prove to be a valid therapeutic target 
for inflammation resolution and the treatment of the myriad of diseases plaguing today’s patient 
populations. 
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